ArticleClinical and translational science2018
Association Between Serotonin Syndrome and Second-Generation Antipsychotics via Pharmacological Target-Adverse Event Analysis.
Article in Clinical and translational science, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 43 citations in OpenAlex.
- Disproportionality analysis of serotonin syndrome associated with selective serotonin reuptake inhibitors: a pharmacovigilance analysis.European journal of clinical pharmacology · 2025Article
- Rewiring Drug Research and Development through Human Data-Driven Discovery (HDPharmaceutics · 2023Review
- Review
- Recognition and Management of Serotonin Toxidrome in the Emergency Department-Case Based Review.Journal of personalized medicine · 2022Review
- Advancing drug safety science by integrating molecular knowledge with post-marketing adverse event reports.CPT: pharmacometrics & systems pharmacology · 2022Review
- Molecular Features Triggered by Antipsychotic Medication in Brain Cells.Advances in experimental medicine and biology · 2022Article
- Increased Sensitivity to Serotonin Syndrome in Cerebral Palsy.Case reports in psychiatry · 2022Article
- Drug repurposing of selective serotonin reuptake inhibitors: Could these drugs help fight COVID-19 and save lives?Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia · 2021Review
- Target Adverse Event Profiles for Predictive Safety in the Postmarket Setting.Clinical pharmacology and therapeutics · 2021Article
- Use of multiple anticholinergic medications can predispose patients to severe non-exertional hyperthermia.BMJ case reports · 2021Article
- Public Adverse Event Data Insights into the Safety of Pembrolizumab in Melanoma Patients.Cancers · 2020Article
- Clinical Relevance of Pharmacogenetics in Serotonin Syndrome.Case reports in psychiatry · 2020Article
- Radioimmunotherapy in Non-Hodgkin's Lymphoma: Retrospective Adverse Event Profiling of Zevalin and Bexxar.Pharmaceuticals (Basel, Switzerland) · 2019Article
- Retrospective Toxicological Profiling of Radium-223 Dichloride for the Treatment of Bone Metastases in Prostate Cancer Using Adverse Event Data.Medicina (Kaunas, Lithuania) · 2019Article
- Adverse Event Circumstances and the Case of Drug Interactions.Healthcare (Basel, Switzerland) · 2019Article
- Use of a Bioinformatics-Based Toxicity Scoring System to Assess Serotonin Burden and Predict Population-Level Adverse Drug Events from Concomitant Serotonergic Drug Therapy.Pharmacotherapy · 2019Article
- Examining Socioeconomic and Computational Aspects of Vaccine Pharmacovigilance.BioMed research international · 2019Article
- Serotonin Syndrome: Pathophysiology, Clinical Features, Management, and Potential Future Directions.International journal of tryptophan research : IJTR · 2019Review
- Target-Adverse Event Profiles to Augment Pharmacovigilance: A Pilot Study With Six New Molecular Entities.CPT: pharmacometrics & systems pharmacology · 2018Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Case reports suggest an association between second-generation antipsychotics (SGAs) and serotonin syndrome (SS). The US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) was analyzed to generate hypotheses about how SGAs may interact with pharmacological targets associated with SS. FAERS was integrated with additional sources to link information about adverse events with drugs and targets. Using Proportional Reporting Ratios, we identified signals that were further investigated with the literature to evaluate mechanistic hypotheses formed from the integrated FAERS data. Analysis revealed common pharmacological targets perturbed in both SGA and SS cases, indicating that SGAs may induce SS. The literature also supported 5-HT
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.